SURGERY PARTNERS INC (SGRY)
US86881A1007 - Common Stock
Overall SGRY gets a fundamental rating of 3 out of 10. We evaluated SGRY against 107 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of SGRY while its profitability can be described as average. SGRY is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SGRY had positive earnings in the past year.
SGRY had a positive operating cash flow in the past year.
SGRY had negative earnings in each of the past 5 years.
In the past 5 years SGRY always reported a positive cash flow from operatings.
1.2 Ratios
SGRY has a Return On Assets (-0.80%) which is in line with its industry peers.
SGRY has a Return On Equity of -3.20%. This is comparable to the rest of the industry: SGRY outperforms 52.38% of its industry peers.
SGRY has a Return On Invested Capital of 5.07%. This is comparable to the rest of the industry: SGRY outperforms 60.00% of its industry peers.
SGRY had an Average Return On Invested Capital over the past 3 years of 4.74%. This is below the industry average of 8.15%.
The last Return On Invested Capital (5.07%) for SGRY is above the 3 year average (4.74%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.8% | ||
| ROE | -3.2% | ||
| ROIC | 5.07% |
ROA(3y)-0.77%
ROA(5y)-1.48%
ROE(3y)-3.6%
ROE(5y)-11.01%
ROIC(3y)4.74%
ROIC(5y)4.35%
1.3 Margins
SGRY's Operating Margin of 14.98% is amongst the best of the industry. SGRY outperforms 90.48% of its industry peers.
SGRY's Operating Margin has been stable in the last couple of years.
The Gross Margin of SGRY (26.59%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SGRY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.98% | ||
| PM (TTM) | N/A | ||
| GM | 26.59% |
OM growth 3Y14.22%
OM growth 5Y1.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.06%
GM growth 5Y-0.98%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SGRY is destroying value.
Compared to 1 year ago, SGRY has more shares outstanding
Compared to 5 years ago, SGRY has more shares outstanding
The debt/assets ratio for SGRY is higher compared to a year ago.
2.2 Solvency
SGRY has an Altman-Z score of 0.83. This is a bad value and indicates that SGRY is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SGRY (0.83) is worse than 66.67% of its industry peers.
The Debt to FCF ratio of SGRY is 19.53, which is on the high side as it means it would take SGRY, 19.53 years of fcf income to pay off all of its debts.
With a Debt to FCF ratio value of 19.53, SGRY perfoms like the industry average, outperforming 55.24% of the companies in the same industry.
A Debt/Equity ratio of 1.63 is on the high side and indicates that SGRY has dependencies on debt financing.
SGRY has a Debt to Equity ratio of 1.63. This is in the lower half of the industry: SGRY underperforms 75.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.63 | ||
| Debt/FCF | 19.53 | ||
| Altman-Z | 0.83 |
ROIC/WACC0.66
WACC7.73%
2.3 Liquidity
SGRY has a Current Ratio of 1.80. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
SGRY has a Current ratio of 1.80. This is in the better half of the industry: SGRY outperforms 68.57% of its industry peers.
A Quick Ratio of 1.66 indicates that SGRY should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.66, SGRY is in the better half of the industry, outperforming 63.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.66 |
3. Growth
3.1 Past
SGRY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.63%, which is quite good.
Looking at the last year, SGRY shows a quite strong growth in Revenue. The Revenue has grown by 9.96% in the last year.
Measured over the past years, SGRY shows a quite strong growth in Revenue. The Revenue has been growing by 9.14% on average per year.
EPS 1Y (TTM)14.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)9.96%
Revenue growth 3Y13.83%
Revenue growth 5Y9.14%
Sales Q2Q%14.29%
3.2 Future
The Earnings Per Share is expected to grow by 15.88% on average over the next years. This is quite good.
Based on estimates for the next years, SGRY will show a quite strong growth in Revenue. The Revenue will grow by 10.64% on average per year.
EPS Next Y-8.01%
EPS Next 2Y1.64%
EPS Next 3Y9.32%
EPS Next 5Y15.88%
Revenue Next Year11.94%
Revenue Next 2Y10.94%
Revenue Next 3Y10.38%
Revenue Next 5Y10.64%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 22.65 indicates a rather expensive valuation of SGRY.
SGRY's Price/Earnings ratio is a bit cheaper when compared to the industry. SGRY is cheaper than 66.67% of the companies in the same industry.
SGRY is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.09, which is the current average of the S&P500 Index.
SGRY is valuated rather expensively with a Price/Forward Earnings ratio of 20.82.
Based on the Price/Forward Earnings ratio, SGRY is valued a bit cheaper than 63.81% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.45, SGRY is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.65 | ||
| Fwd PE | 20.82 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SGRY indicates a somewhat cheap valuation: SGRY is cheaper than 76.19% of the companies listed in the same industry.
78.10% of the companies in the same industry are more expensive than SGRY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.56 | ||
| EV/EBITDA | 9.48 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.64%
EPS Next 3Y9.32%
5. Dividend
5.1 Amount
No dividends for SGRY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SURGERY PARTNERS INC
NASDAQ:SGRY (1/2/2025, 8:00:02 PM)
After market: 21.29 0 (0%)21.29
+0.12 (+0.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners74.05%
Inst Owner Change-4.22%
Ins Owners1.11%
Ins Owner Change0.25%
Market Cap2.71B
Analysts78.89
Price Target35.63 (67.36%)
Short Float %14.38%
Short Ratio9.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.52%
Min EPS beat(2)-26.04%
Max EPS beat(2)2.99%
EPS beat(4)3
Avg EPS beat(4)6.96%
Min EPS beat(4)-26.04%
Max EPS beat(4)37.02%
EPS beat(8)7
Avg EPS beat(8)279.34%
EPS beat(12)8
Avg EPS beat(12)143.98%
EPS beat(16)12
Avg EPS beat(16)146.7%
Revenue beat(2)1
Avg Revenue beat(2)-0.15%
Min Revenue beat(2)-1.88%
Max Revenue beat(2)1.58%
Revenue beat(4)2
Avg Revenue beat(4)-0.59%
Min Revenue beat(4)-2.77%
Max Revenue beat(4)1.58%
Revenue beat(8)3
Avg Revenue beat(8)-0.76%
Revenue beat(12)4
Avg Revenue beat(12)-1.17%
Revenue beat(16)6
Avg Revenue beat(16)-0.97%
PT rev (1m)-6.05%
PT rev (3m)-11.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.4%
EPS NY rev (1m)-0.78%
EPS NY rev (3m)-15.65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.65 | ||
| Fwd PE | 20.82 | ||
| P/S | 0.91 | ||
| P/FCF | 16.56 | ||
| P/OCF | 10.77 | ||
| P/B | 1.43 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.48 |
EPS(TTM)0.94
EY4.42%
EPS(NY)1.02
Fwd EY4.8%
FCF(TTM)1.29
FCFY6.04%
OCF(TTM)1.98
OCFY9.29%
SpS23.49
BVpS14.92
TBVpS-23.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.8% | ||
| ROE | -3.2% | ||
| ROCE | 6.43% | ||
| ROIC | 5.07% | ||
| ROICexc | 5.24% | ||
| ROICexgc | 18.8% | ||
| OM | 14.98% | ||
| PM (TTM) | N/A | ||
| GM | 26.59% | ||
| FCFM | 5.47% |
ROA(3y)-0.77%
ROA(5y)-1.48%
ROE(3y)-3.6%
ROE(5y)-11.01%
ROIC(3y)4.74%
ROIC(5y)4.35%
ROICexc(3y)4.98%
ROICexc(5y)4.55%
ROICexgc(3y)18.31%
ROICexgc(5y)17.7%
ROCE(3y)6.01%
ROCE(5y)5.51%
ROICexcg growth 3Y8.18%
ROICexcg growth 5Y-7.94%
ROICexc growth 3Y17.44%
ROICexc growth 5Y2.3%
OM growth 3Y14.22%
OM growth 5Y1.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.06%
GM growth 5Y-0.98%
F-Score3
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.63 | ||
| Debt/FCF | 19.53 | ||
| Debt/EBITDA | 5.18 | ||
| Cap/Depr | 58.68% | ||
| Cap/Sales | 2.94% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 42.09% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.66 | ||
| Altman-Z | 0.83 |
F-Score3
WACC7.73%
ROIC/WACC0.66
Cap/Depr(3y)67.9%
Cap/Depr(5y)69.03%
Cap/Sales(3y)3%
Cap/Sales(5y)3.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-8.01%
EPS Next 2Y1.64%
EPS Next 3Y9.32%
EPS Next 5Y15.88%
Revenue 1Y (TTM)9.96%
Revenue growth 3Y13.83%
Revenue growth 5Y9.14%
Sales Q2Q%14.29%
Revenue Next Year11.94%
Revenue Next 2Y10.94%
Revenue Next 3Y10.38%
Revenue Next 5Y10.64%
EBIT growth 1Y10.64%
EBIT growth 3Y30.01%
EBIT growth 5Y10.74%
EBIT Next Year28.99%
EBIT Next 3Y16.85%
EBIT Next 5YN/A
FCF growth 1Y64.55%
FCF growth 3Y0.16%
FCF growth 5Y14.36%
OCF growth 1Y46.7%
OCF growth 3Y5.97%
OCF growth 5Y15.23%